-

TCOM Investor Alert: Trip.com Group Limited Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Active Antitrust Scrutiny: Levi & Korsinsky

Alert: Claims Focus on Alleged Misrepresentations About Anti-Monopoly Enforcement Risk

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP reminds purchasers of Trip.com Group Limited (NASDAQ: TCOM) securities of a pending securities class action.

THE CASE: A class action seeks to recover damages for investors who purchased Trip.com securities between April 30, 2024 and January 13, 2026.

YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. See if you can recover losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Trip.com ADSs plunged $12.90 per share (17.05%) on January 14, 2026, with an additional $1.48 per share (2.35%) decline the following day, after Bloomberg reported that China's State Administration for Market Regulation had launched an antitrust probe into the company. Investors have until May 11, 2026 to seek lead plaintiff status.

The Alleged Anti-Monopoly Enforcement Acceleration

An online travel platform operating as the dominant player in China's travel booking market cannot treat regulatory scrutiny as a hypothetical future possibility when enforcement activity is already escalating against it, the lawsuit contends. Trip.com's SEC filings framed anti-monopoly risk in conditional terms, stating that its business "could" be adversely affected. Yet as the complaint details, enforcement was not speculative. Months before the formal SAMR investigation announcement, regional regulators in Guizhou and Zhengzhou had already summoned Trip.com and other travel platforms over antitrust concerns and alleged violations of rules against imposing unfair restrictions on merchants.

Regulatory Management and the Qunar Acquisition Legacy

The filing states that Trip.com's 2015 acquisition of Qunar, a competing travel platform, sits at the center of the regulatory exposure. Trip.com's own annual reports acknowledged that the Qunar transaction and its business cooperation arrangements with Qunar could be deemed violations of the PRC Anti-Monopoly Law. The penalties for such violations are severe: fines of up to 10% of annual sales revenue, orders to cease concentration activities, or mandated unwinding of prohibited transactions. Despite these acknowledged risks, the action claims, management presented them as uncertain possibilities rather than as an active and accelerating enforcement concern.

Alleged Anti-Monopoly Impact by the Numbers

- The SAMR accused Trip.com of "abusing its market position and engaging in monopolistic practices," as alleged in the complaint

- In August 2025, Guizhou's market regulator summoned five online tourism platforms to discuss potential antitrust concerns, the lawsuit chronicles

- In September 2025, Zhengzhou's market regulator summoned Trip.com specifically for alleged violations related to unfair merchant restrictions

- The PRC Anti-Monopoly Law permits fines of up to 10% of a company's prior-year sales revenue for prohibited concentrations

- Trip.com's Qunar acquisition in 2015 remained under regulatory uncertainty for over a decade, as detailed in the action

- Two consecutive trading days of losses totaled $14.38 per ADS, bringing shares to $61.30

Calculate your potential recovery or call (212) 363-7500.

"The complaint raises serious questions about whether investors received accurate information regarding the trajectory of regulatory enforcement that was already underway against Trip.com in multiple Chinese provinces." -- Joseph E. Levi, Esq.

Get more information about this case or contact Joseph E. Levi, Esq. at (212) 363-7500.

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Levi & Korsinsky, LLP

NASDAQ:TCOM

Release Versions

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

More News From Levi & Korsinsky, LLP

MO Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Altria Group (MO)

NEW YORK--(BUSINESS WIRE)--Altria Group (NYSE: MO) shareholders took losses in late July 2026 when the Company reported second-quarter earnings and revenue below consensus and cut its full-year outlook -- an outlook management had reaffirmed on April 30, 2026 at adjusted diluted EPS of $5.56 to $5.72. If you suffered a loss on your Altria Group investment, you are encouraged to click here to submit your Altria loss information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikor...

TDOC Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Teladoc Health (TDOC)

NEW YORK--(BUSINESS WIRE)--Five months after guiding full-year 2026 consolidated revenue to a range of $2.47 billion to $2.59 billion, Teladoc Health (NYSE: TDOC) reduced that outlook to $2.36 billion to $2.45 billion, and shares fell nearly 30%. If you lost money holding Teladoc Health shares, you are encouraged to submit your loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.On the February 25, 2026 fourth qua...

PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)

NEW YORK--(BUSINESS WIRE)--A 22% single-session drop hit Pharming Group (PHAR) shares today after the Company reported Q2 2026 revenue of $90.2 million -- a 3% year-over-year decline against analyst consensus of roughly $419 million for the full year. If you lost money on PHAR, click here to submit your losses for review. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.The miss came from the Company's legacy product. RUCONEST sales...
Back to Newsroom